Victoza®
Victoza® is a pharmaceutical drug with 10 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults
Incretin-based Therapy in Late Preclinical Type 1 Diabetes
Human Bioequivalence Test of Liraglutide Injection
Clinical Trials (10)
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults
Incretin-based Therapy in Late Preclinical Type 1 Diabetes
Human Bioequivalence Test of Liraglutide Injection
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10